H.C. Wainwright raised the firm’s price target on Maze Therapeutics (MAZE) to $60 from $50 and keeps a Buy rating on the shares. The firm believes MZE829 is a “best-in-class” APOL1 inhibitor. It cites a key opinion leader discussion and its understanding of the APOL1-mediated kidney disease market for the target boost.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- Maze Therapeutics initiated with a Strong Buy at Raymond James
- Maze Therapeutics Reports Strong Q3 2025 Progress
- Promising Developments in Maze Therapeutics’ Pipeline: Buy Rating Reinforced by MZE829 and MZE782 Advances
- Maze Therapeutics reports Q3 EPS (66c), consensus (69c)
- Maze Therapeutics Advances Kidney Disease Treatment with MZE829 Study